The promoter methylation of the ABCG1, GALNT2 and HMGCR genes was detected in 91.2%, 52.6%, and 31.6% of the male CHD patients, while that of the male non-CHD subjects is 34.4%, 28.1%, and 21.9%. This evidence concerns the gene ABCG1 and coronary artery disorder.